Dov A. Goldstein, MD
Known title: Chief Financial OfficerCIK: 0001120478
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
COYA completes enrollment for Phase 2/3 ALS trial. Coya Therapeutics announced that the planned enrollment of 120 patients in its Phase 2/3 ALSTARS trial of COYA-302 for amyotrophic lateral sclerosis has been completed. Full enrollment is a key step toward generating efficacy data for the ALS indication. The news arrives as the stock is trading near its $4.65 support level, which has been tested multiple times.
Transaction History
| BIOA | ▲ Buy | Option Exercise | 3,542 | $16K | 4/23/2026 | View on chart |
| BIOA | ▲ Buy | Option Exercise | 3,542 | $16K | 3/1/2026 | View on chart |
| BIOA | ▲ Buy | Option Exercise | 3,541 | $16K | 2/1/2026 | View on chart |
| BIOA | ▲ Buy | Option Exercise | 3,542 | $16K | 1/16/2026 | View on chart |
| BIOA | ▼ Sell | Open Market | 8,974 | $165K | 1/13/2026 | View on chart |
| BIOA | ▼ Sell | Open Market | 4,440 | $86K | 1/13/2026 | View on chart |
| BIOA | ▼ Sell | Open Market | 11,663 | $240K | 1/13/2026 | View on chart |
| BIOA | ▼ Sell | Open Market | 1,923 | $41K | 1/13/2026 | View on chart |
| BIOA | ▲ Buy | Option Exercise | 27,000 | $227K | 1/13/2026 | View on chart |
| COYA | ▲ Buy | Option Exercise | 17,557 | $19K | 8/18/2025 | View on chart |
| COYA | ▲ Buy | Open Market | 10,000 | — | 1/3/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
BioAge Labs to Present at Investor Conferences
BioAge Labs announced it will present at upcoming investor conferences, providing a platform to share company updates with the market. The stock is currently trading near its 52-week low, which may increase attention from investors seeking value. This corporate activity adds context to the recent whale alerts noted in healthcare stocks.
BioAge Labs to Present at Investor Conferences. BioAge Labs announced it will present at upcoming investor conferences, providing a platform to share company updates with the market. The stock is currently trading near its 52-week low, which may increase attention from investors seeking value. This corporate activity adds context to the recent whale alerts noted in healthcare stocks.